3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasm Metastasis
5
Colorectal Neoplasms
5
Pancreatic Neoplasms
4
Sarcoma
3
Insulin-Like Growth Factor I, Resistance To
3
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Adenocarcinoma
2
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Pleural Effusion, Malignant
1
Neuroectodermal Tumors, Primitive
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Jaundice
1
Gastrointestinal Neoplasms
1
Endocrine Gland Neoplasms
1
Carcinoid Tumor
1
Askin Tumor
1
Interventions
Cisplatin
4
Carboplatin
2
viscum album peptide
1
sugemalimab
1
rilotumumab
1
ganitumab
1
endostar protein
1
Zoledronic Acid
1
Valacyclovir
1
Thiostrepton
1
Surgical Procedures, Operative
1
Paclitaxel
1
N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea
1
Etoposide
1
Darbepoetin alfa
1
Cetuximab
1
Catheters, Indwelling
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pleural Effusion, Malignant
×
ganitumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts